Related Experiment Video
Updated: Jun 14, 2026
03:35
Rapid Quantification of Oxidized and Reduced Forms of Glutathione Using Ortho -phthalaldehyde in Cultured Mammalian Cells In Vitro
Published on: June 28, 2024
Prodrug approach for increasing cellular glutathione levels
Ivana Cacciatore1, Catia Cornacchia, Francesco Pinnen
1Department of Drug Sciences, School of Pharmacy, G. d'Annunzio University, Via dei Vestini 31, 66100 Chieti, Italy.
Molecules (Basel, Switzerland)
|March 26, 2010
Summary
This review explores strategies to boost cellular reduced glutathione (GSH) levels using prodrugs. These compounds, designed to overcome GSH
Area of Science:
- Biochemistry
- Cellular Biology
- Pharmacology
Background:
- Reduced glutathione (GSH) is a critical intracellular thiol vital for antioxidant defense and xenobiotic metabolism.
- GSH plays a role in cellular processes like differentiation, proliferation, and apoptosis.
- GSH deficiency is linked to aging, neurodegenerative diseases, cystic fibrosis, and viral infections.
Purpose of the Study:
- To review strategies for increasing intracellular GSH levels.
- To discuss the use of GSH prodrugs as a therapeutic approach.
- To explore reversible bioconjugates for enhanced GSH synthesis.
Main Methods:
- Literature review of existing research on GSH prodrugs.
- Analysis of strategies for improving GSH bioavailability.
- Discussion of bioconjugate properties for cellular uptake.
Main Results:
- GSH's therapeutic use is limited by poor biochemical and pharmacokinetic properties.
- GSH prodrugs show potential for replenishing intracellular GSH levels.
- Reversible bioconjugates can facilitate cellular membrane crossing and provide thiol sources.
Conclusions:
- Developing effective GSH prodrugs is crucial for therapeutic applications.
- Bioconjugate strategies offer a promising avenue for enhancing GSH synthesis.
- Further research into these strategies could address GSH deficiency-related pathologies.
Related Concept Videos
01:22Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
01:14Drug Metabolism: Phase II Reactions
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
01:24Phase II Reactions: Glucuronidation
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
01:19Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme activation, sulfur...
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...